Cargando…

Adenovirus vector-based vaccine for infectious diseases

Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transge...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Fuminori, Tachibana, Masashi, Mizuguchi, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585960/
https://www.ncbi.nlm.nih.gov/pubmed/34974335
http://dx.doi.org/10.1016/j.dmpk.2021.100432
_version_ 1784597796543791104
author Sakurai, Fuminori
Tachibana, Masashi
Mizuguchi, Hiroyuki
author_facet Sakurai, Fuminori
Tachibana, Masashi
Mizuguchi, Hiroyuki
author_sort Sakurai, Fuminori
collection PubMed
description Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed.
format Online
Article
Text
id pubmed-8585960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85859602021-11-12 Adenovirus vector-based vaccine for infectious diseases Sakurai, Fuminori Tachibana, Masashi Mizuguchi, Hiroyuki Drug Metab Pharmacokinet Review Article Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed. The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. 2022-02 2021-11-12 /pmc/articles/PMC8585960/ /pubmed/34974335 http://dx.doi.org/10.1016/j.dmpk.2021.100432 Text en © 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Sakurai, Fuminori
Tachibana, Masashi
Mizuguchi, Hiroyuki
Adenovirus vector-based vaccine for infectious diseases
title Adenovirus vector-based vaccine for infectious diseases
title_full Adenovirus vector-based vaccine for infectious diseases
title_fullStr Adenovirus vector-based vaccine for infectious diseases
title_full_unstemmed Adenovirus vector-based vaccine for infectious diseases
title_short Adenovirus vector-based vaccine for infectious diseases
title_sort adenovirus vector-based vaccine for infectious diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585960/
https://www.ncbi.nlm.nih.gov/pubmed/34974335
http://dx.doi.org/10.1016/j.dmpk.2021.100432
work_keys_str_mv AT sakuraifuminori adenovirusvectorbasedvaccineforinfectiousdiseases
AT tachibanamasashi adenovirusvectorbasedvaccineforinfectiousdiseases
AT mizuguchihiroyuki adenovirusvectorbasedvaccineforinfectiousdiseases